Rose Marie Haynes

Rose Marie Haynes

Auto-generated profile, based on publicly available information

Rose Marie Haynes

Pacific Northwest Center for Cryo-Electron Microscopy, Oregon Health & Science University, Portland, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2023 in Blood
Verified
Journal Article
Open access
PDF file
KCKenneth C. Childers
Kenneth C. Childers
NANathan G. Avery
Nathan G. Avery
KAKevin Alexander Estrada Alamo
Kevin Alexander Estrada Alamo
ODOmar Davulcu
Omar Davulcu
RHRose Marie Haynes
Rose Marie Haynes
PSPaul Clinton Spiegel
Paul Clinton Spiegel
The development of pathogenic antibody inhibitors against coagulation factor VIII (FVIII) occurs in approximately 30% of congenital hemophilia A patients receiving FVIII replacement therapy as well as in all cases of acquired hemophilia A. KM33 is an anti-C1 domain antibody inhibitor previously isolated from a severe hemophilia A patient. In addition to potently blocking FVIII binding to von Willebrand factor and phospholipid surfaces, KM33 disrupts FVIII binding to lipoprotein receptor-related protein 1 (LRP1), which drives FVIII hepatic clearance and antigen presentation in dendritic cells. Here, we report on the structure of FVIII bound to NB33, a recombinant derivative of KM33, by single-particle cryo-electron microscopy. Structural analysis reveals the NB33 epitope localizes to FVIII residues R2090-S2094 and I2158-R2159 which constitute membrane-binding loops in the C1 domain. Further analysis reveals multiple FVIII lysine and arginine residues, previously shown to mediate binding to LRP1, dock onto an acidic cleft at the NB33 variable domain interface, thus blocking a putative LRP1 binding site. Together, these results demonstrate a novel mechanism of FVIII inhibition by a patient-derived antibody inhibitor and provide structural evidence toward engineering FVIII with reduced LRP1-mediated clearance.

14 July 2017 in The Astronomical Journal
Verified
Journal Article
Closed access
PDF file
JHJoanne Hughes
Joanne Hughes
BLBrianna Lacy
Brianna Lacy
CSCharli Sakari
Charli Sakari
GWGeorge Wallerstein
George Wallerstein
CDChristoper Evan Davis
Christoper Evan Davis
RHRose Marie Haynes
Rose Marie Haynes
We present new SDSS and Washington photometry of the young outer-halo stellar system Segue 3. Combined with archival VI-observations, our most consistent results yield , , , and , with a high binary fraction of 0.39 ± 0.05 derived using the Padova models. We confirm that mass-segregation has occurred, supporting the hypothesis that this cluster is being tidally disrupted. A three-parameter King model yields a cluster radius of , a core radius of , and a tidal radius of . A comparison of Padova and Dartmouth model-grids indicates that the cluster is not significantly α-enhanced, with a mean dex, and a population age of only 2.6 ± 0.4 Gyr. We rule out a statistically significant age spread at the main-sequence turnoff because of a narrow subgiant branch, and discuss the role of stellar rotation and cluster age, using Dartmouth and Geneva models: approximately 70% of the Seg 3 stars at or below the main-sequence turnoff have enhanced rotation. Our results for Segue 3 indicate that it is younger and more metal-rich than all previous studies have reported to date. From colors involving Washington C and SDSS-u filters, we identify several giants and a possible blue straggler for future follow-up spectroscopic studies, and we produce spectral energy distributions of previously known members and potential Segue 3 sources with Washington (CT 1), Sloan (ugri), and VI-filters. Segue 3 shares the characteristics of unusual stellar systems that have likely been stripped from external dwarf galaxies as they are being accreted by the Milky Way, or that have been formed during such an event. Its youth, metallicity, and location are all inconsistent with Segue 3 being a cluster native to the Milky Way.

8 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
YNYoung-Woo Nam
Young-Woo Nam
ARAlena Ramanishka
Alena Ramanishka
YXYang Xu
Yang Xu
RYRose Marie Haynes Yasuda
Rose Marie Haynes Yasuda
JNJoshua A. Nasburg
Joshua A. Nasburg
MZMiao Zhang
Miao Zhang
Small-conductance (KCa2.2) and intermediate-conductance (KCa3.1) Ca2+-activated K+ channels are gated by a Ca2+-calmodulin dependent mechanism. NS309 potentiates the activity of both KCa2.2 and KCa3.1, while rimtuzalcap selectively activates KCa2.2. Rimtuzalcap has been used in clinical trials for the treatment of spinocerebellar ataxia and essential tremor. We report cryo-electron microscopy structures of NS309-bound KCa2.2 and KCa3.1, in addition to structures of rimtuzalcap-bound KCa2.2 and mutant KCa3.1_R355K. The different conformations of calmodulin and the cytoplasmic HC helices in the two channels underlie the subtype-selectivity of rimtuzalcap for KCa2.2. NS309 binds to pre-existing pockets in both channels, while the bulkier rimtuzalcap binds in an induced-fit pocket in KCa2.2 requiring conformational changes. In KCa2.2, calmodulin’s N-lobes are sufficiently far apart to enable conformational changes to accommodate either NS309 or rimtuzalcap. In KCa3.1, calmodulin’s N-lobes are closer to each other and constrained by KCa3.1’s HC helices, which allows binding of NS309 but not rimtuzalcap. Replacement of arginine-355 in KCa3.1’s HB helix with lysine (KCa3.1_R355K) allows the binding of rimtuzalcap and renders the mutant channel sensitive to rimtuzalcap. These structures provide a framework for structure-based drug design targeting KCa2.2 channels.

16 May 2025 in Research Square
Verified
Preprint
Open access
PDF file
MZMiao Zhang
Miao Zhang
YNYoung-Woo Nam
Young-Woo Nam
ARAlena Ramanishka
Alena Ramanishka
YXYang Xu
Yang Xu
RYRose Marie Yasuda
Rose Marie Yasuda
HWHeike Wulff
Heike Wulff
Small-conductance (K Ca 2.2) and intermediate-conductance (K Ca 3.1) Ca 2+ -activated K + channels are gated by a Ca 2+ -calmodulin dependent mechanism. NS309 potentiates the activity of both K Ca 2.2 and K Ca 3.1, while rimtuzalcap selectively activates K Ca 2.2. Rimtuzalcap has been used in clinical trials for the treatment of spinocerebellar ataxia and essential tremor. We report cryo-electron microscopy structures of K Ca 2.2 channels bound with NS309 and rimtuzalcap, in addition to K Ca 3.1 channels with NS309. The different conformations of calmodulin and the cytoplasmic HC helices in the two channels underlie the subtype-selectivity of rimtuzalcap for K Ca 2.2. Calmodulin’s N-lobes in the K Ca 2.2 structure are far apart and undergo conformational changes to accommodate either NS309 or rimtuzalcap. Calmodulin’s N-lobes in the K Ca 3.1 structure are closer to each other and are constrained by the HC helices of K Ca 3.1, which allows binding of NS309 but not of the bulkier rimtuzalcap. These structures provide a framework for structure-based drug design targeting K Ca 2.2 channels.